Technavio has published a new report on the drug development pipeline for the treatment of candidiasis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
Technavio has announced their latest pipeline analysis report on the drug pipeline for candidiasis. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat candidiasis.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180910005700/en/
Technavio has published a new report on the drug development pipeline for the treatment of candidiasis, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market.
This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing
Candidiasis: Market overview
Candidiasis can be defined as a fungal infection caused by yeasts that belong to the genus Candida. Imbalance in normal flora in the mouth and throat makes a suitable environment for the fungus to multiply, which can lead to candidiasis.
According to a senior market research analyst at Technavio, “As per the Centers for Disease Control and Prevention, in 2015, around 75% of women had at least one episode of vulvovaginal candidiasis, and 40% had at least two or more episodes of VVC globally.”
Candidiasis: Segmentation analysis
This pipeline analysis report segments the candidiasis market based on therapies employed (monotherapy), RoA (oral, topical, IV, intravaginal, and intramuscular), therapeutic modality (small molecule and vaccine), targets (glucan synthase, 14-alpha demethylase, cyclooxygenase, and Gwt1 enzyme), MoA (glucan synthase inhibitor, 14-alpha demethylase inhibitor, cyclooxygenase inhibitor, Gwt1 enzyme inhibitor, and immunostimulator), geographical segmentation (the US and Austria) and recruitment status (recruiting, completed, not yet recruiting, and enrolling by invitation). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.
Based on therapeutic modality, more than 57% of the molecules that are being investigated for the treatment of candidiasis are small molecules.
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Regulatory Framework
Drug Development Landscape
Drug Development Strategies
Recruitment Strategies
Key Companies
Discontinued or Dormant Molecules
About Technavio
Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at media@technavio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180910005700/en/
Technavio Research
Jesse Maida
Media & Marketing Executive
US:
+1 844 364 1100
UK: +44 203 893 3200
www.technavio.com